AFT Pharmaceuticals looks ahead to Maxigesic US licensing windfall

AFT Pharmaceuticals looks ahead to Maxigesic US licensing windfall
David Flacks says the fact that Maxigesic pain relief medicine has been approved for sale by the US Food and Drug Administration in a first for NZ. (Image: AFT Pharmaceuticals)
Staff reporters
AFT Pharmaceuticals is expecting at least $6 million in licensing income from the United States launch of its Maxigesic patented pain-relief medicine, but isn’t yet sure when that will come in.The dual New Zealand and Australian stock market-listed pharmaceutical company told its annual shareholder meeting on Aug 4 that the licensing income for its Maxigesic IV medicine could arrive near the end of the March 31, 2024, financial year or early in the 2025 year.Chair David Flacks said a prescription-only version of AFT's Maxigesic p...